Navigation Links
Prism Glasses Expand the View for Patients with Hemianopia
Date:5/12/2008

Schepens study opens way for high-power permanent version of the glasses

and larger new study

BOSTON, May 12 /PRNewswire/ -- Innovative prism glasses can significantly improve the vision and the daily lives of patients with hemianopia, a condition that blinds half the visual field in both eyes. The peripheral prism glasses, which were invented by Dr. Eli Peli, a Senior Scientist at Schepens Eye Research Institute, were evaluated in the first community-based multi- center trial of such a device, which is published in the May issue of the Archives of Ophthalmology. The study was coordinated by Dr. Alex Bowers, a Senior Scientific Associate at the Institute.

"This is the first real breakthrough in the rehabilitation of patients with this condition," says Peli, a world-renowned low vision expert, the Moakley Scholar in Aging Eye Research at Schepens and a Professor of Ophthalmology at Harvard Medical School. Peli had searched for a solution for his hemianopia patients for many years before designing the peripheral prism glasses, creating a prototype in his laboratory.

More than a million Americans suffer from hemianopia, which blinds the vision in one half of the visual field in both eyes, resulting from damage to the optic pathways in the brain. Most commonly caused by strokes, it can also be the result of brain damage from tumors or trauma. A patient with this condition may be unaware of what he or she cannot see and frequently bumps into walls, trips over objects or walks into people on the side where the visual field is missing.

Peli's goal was to find a way to expand the visual field. He did this by attaching small, specially designed high power prisms on the top and bottom of one spectacle lens, leaving the center of the lens untouched. The prisms pull in images missing from the visual field above and below the line of sight on the side of the vision loss, and alert the patient to the presence of a pot
'/>"/>

SOURCE Schepens Eye Research Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
2. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
3. CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts
4. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
5. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
6. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
7. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. PAREXEL Expands Global Clinical Pharmacology Capabilities
10. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
11. Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...IANAPOLIS, Dec. 1 Roche announced ...ate differences in perceived pain and,discomfort ...CHEK blood,glucose monitoring systems and lancing...ts indicated that, overall, the ACCU-CHEK Aviva an... systems and the ACCU-CHEK Multiclix, ACCU-CHEK,S...
(Date:12/1/2008)...MOUTH MEETING, Pa., Dec. 1 /PRNewswire-FirstCall/ ...nounced that dosing of subjects has begun in study... dose Phase 1b study of trodusquemine (MSI-1436) i...is a novel therapeutic for the treatment of type 2...ripherally to regulate insulin and leptin pathways...
(Date:12/1/2008)... DIEGO, Dec. 1 Vical Inc...ceipt of a $1.0 million milestone payment from Mer...tion of a Phase I clinical trial of an investigati...ate vaccine is based on Vical,s DNA gene delivery ...anscriptase (hTERT). hTERT is the subject of separ...
(Date:11/28/2008)...IANAPOLIS, Nov. 28 Eli L... supplemental New Drug Application (sNDA) from,th...alta(R) (duloxetine HCl),for the management of ch...n in,the first half of 2009, adding data from a r...arthritis pain of the knee. , The decision ...
Breaking Medicine Technology:Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Groups Call On Senator Charles Schumer to Lead Senate In Strengthening Medicare 7313 1Groups Call On Senator Charles Schumer to Lead Senate In Strengthening Medicare 7313 2Groups Call On Senator Charles Schumer to Lead Senate In Strengthening Medicare 7313 3Announcing Prime Vendor Contract with LIHPA 7310 1Announcing Prime Vendor Contract with LIHPA 7310 2Diets May Raise Cancer Risk for Poor Urban Women 7307 1Diets May Raise Cancer Risk for Poor Urban Women 7307 2SuperArray Bioscience Corporation Licenses RNA Interference Patent From The Carnegie Institution 7305 1SuperArray Bioscience Corporation Licenses RNA Interference Patent From The Carnegie Institution 7305 2
... Nuvion Antibody Led to a Sustained Response and R...dies and Was Adequately,Tolerated in Patients with..., Calif., May 22, 2007 /PRNewswire-FirstCall/ -- D...meeting this week in,Washington D.C. by Dr. Willia...n (visilizumab), an antibody in development as a,t...
... ANN ARBOR, Mich., May 22, 2007 /PRNewswire/ -- N...veloping novel products,for the treatment and prev...tive safety data from its Phase 1 clinical study o...n a Phase 2,clinical trial for the topical treatme...was completed in January 2007 and,involved 20 subj...
Other Medicine Technology:PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007,Digestive Disease Week 2PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007,Digestive Disease Week 3PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007,Digestive Disease Week 4PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007,Digestive Disease Week 5NanoBio Corporation Announces Positive Phase 1 Clinical Results for,Topical Treatment for Onychomycosis 2NanoBio Corporation Announces Positive Phase 1 Clinical Results for,Topical Treatment for Onychomycosis 3
(Date:12/1/2008)...s goals, commitment and resources , , ...riticism that it has done a poor job safeguarding ...dministration released a report Monday detailing i...st important changes in 2008 was the agency,s init...d local health departments to protect the food sup...
(Date:12/1/2008)...er Institute,s cancer registry has found that as m...or incomplete radiation treatment following breast... can lead to worse outcomes. , Dr. Heather Taffe...gues found that among a nationally representative ...ents aged 65 and older, almost 1,300 women experie...
(Date:12/1/2008)...e/ -- Due to the urgent need to disseminate author...rch and clinical care, publisher Mary Ann Lieber...all archival online issues of the company,s AIDS j...rld AIDS Day. Free online access is available for ...m/apc ) and AIDS Research and Human Retroviruses...
(Date:12/1/2008)...wire/ -- Americans United for Life (AUL) today a...resolution opposing the federal "Freedom of Choice...pt the resolution immediately when they convene th... AUL President & CEO said, "The so-called ,Fre...protects and promotes the abortion industry, sacri...
Breaking Medicine News(10 mins):Health News:FDA Touts Efforts to Enhance Food Safety 2Health News:FDA Touts Efforts to Enhance Food Safety 3Health News:FDA Touts Efforts to Enhance Food Safety 4Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:Mary Ann Liebert, Inc. Provides Free Online Journal Access in Recognition of World AIDS Day 2Health News:Americans United for Life Urges State Legislatures to Oppose Federal Power Grab: Provides Model Resolution Denouncing Freedom of Choice Act (FOCA) 2
...y gave the all clear to 21 women who had breast ca... alter" their chances of fighting and surviving th...e cancer diagnosed two years after she was given a...ot being named by hospital bosses in Manchester. T...
...ffering from Motor Neurone Disease (MND), a fatal ...he use of a simple ventilator and facemask//. Pat...ould benefit from the new technique called non-inv...ping people with MND who suffer from weakness of t...
...e can increase the level of mental sharpness in ag...rs from University of Massachusetts at Lowell//. ...uice could protect against brain damage in aging m...to memory loss. Researcher Thomas B. Shea evaluate...
...mall group of patients can provide an adequate rep...uted by private health practitioners and their off...n Journal of General Internal Medicine. Highly co...vided by a group of 45 patients, according to the ...
Other Medicine News:
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
Medicine Products: